Document is current
Any future updates will be listed below
-
Authors
Zhang, Jie https://orcid.org/0000-0003-4119-9442
Petersen, Søren D. https://orcid.org/0000-0003-4104-5144
Radivojevic, Tijana https://orcid.org/0000-0002-7165-2909
Ramirez, Andrés https://orcid.org/0000-0001-6273-5211
Pérez-Manríquez, Andrés https://orcid.org/0000-0003-3803-951X
Abeliuk, Eduardo
Sánchez, Benjamín J.
Costello, Zak
Chen, Yu https://orcid.org/0000-0003-3326-9068
Fero, Michael J. https://orcid.org/0000-0002-4845-7048
Martin, Hector Garcia https://orcid.org/0000-0002-4556-9685
Nielsen, Jens
Keasling, Jay D. https://orcid.org/0000-0003-4170-6088
Jensen, Michael K. https://orcid.org/0000-0001-7574-4707
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden
EC | Horizon 2020 Framework Programme (722287, 686070)
U.S. Department of Energy (DE-AC02- 05CH11231)
Basque Government
- License Information
-
More Information
Article History
Received: 30 December 2019
Accepted: 27 July 2020
First Online: 25 September 2020
Competing interests
: J.D.K. has a financial interest in Amyris, Lygos, Demetrix, Maple Bio, and Napigen. E.A., A.P.-M., A.R., and M.J.F. have a financial interest in TeselaGen Biotechnology. All other authors declare no competing interests.
